Home / Market News / $AXSM
benzinga Corporate Catalyst Impact 55/100 ● negative

Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267

Sep 29, 2026, 2:25 PM UTC · Primary ticker $AXSM

Deutsche Bank analyst David Hoang reiterated a 'Buy' rating on Axsome Therapeutics but reduced the price target from $280 to $267. This indicates a continued positive outlook on the company's fundamentals despite a slightly tempered valuation.

Deutsche Bank's analyst David Hoang maintained a 'Buy' rating on Axsome Therapeutics, signaling continued confidence in the company's long-term prospects. However, the price target was lowered from $280 to $267, suggesting a slight adjustment in valuation expectations, possibly due to updated financial models, market conditions, or competitive landscape. This news is moderately impactful for traders; while the 'Buy' rating is positive, the reduced price target could temper some bullish sentiment. Short-term, it might lead to minor price fluctuations as investors digest the updated valuation. Long-term, the maintained 'Buy' rating suggests continued analyst support, which could be a positive factor for the stock. The key opportunity for traders lies in understanding if this price target adjustment reflects a broader industry trend or specific company-related factors.

$AXSM neutral Analyst rating maintained, price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.